生命科学资讯

Valneva to withdraw Chikungunya vaccine from US amid safety woes

GSK to buy Rapt in $2.2B deal for food allergy drug

Kailera’s Ron Renaud on how a China-linked startup can compete in obesity

The patient retention crisis is happening before enrollment even begins

When every day counts: Building CRO partnerships on a foundation of trust, care and precision

Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

On biotech’s biggest stage, renewed excitement gets a stress test

Trump unveils healthcare affordability plan

Tecvayli tops standard drugs in early multiple myeloma, J&J says

Oxford Biomedica confirms takeover talks with biotech investor EQT

Boston Scientific to acquire Penumbra for $14.5B

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view

Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

Caldera starts up with $112.5M and a dual-targeting immune drug from China

JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target

Digital health funding increases in 2025, spurred by AI: report

What Sanofi’s multiple sclerosis troubles could mean for the space

AbbVie pledges $100B to US production in drug pricing deal with Trump

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations